Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Gross Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Gross Margin for 16 consecutive years, with 64.14% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 166.0% to 64.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 64.28% through Dec 2025, up 244.0% year-over-year, with the annual reading at 64.28% for FY2025, 244.0% up from the prior year.
  • Gross Margin for Q4 2025 was 64.14% at Niagen Bioscience, down from 64.52% in the prior quarter.
  • The five-year high for Gross Margin was 65.0% in Q2 2025, with the low at 57.23% in Q4 2022.
  • Average Gross Margin over 5 years is 61.58%, with a median of 61.1% recorded in 2021.
  • The sharpest move saw Gross Margin skyrocketed 495bps in 2021, then tumbled -397bps in 2022.
  • Over 5 years, Gross Margin stood at 61.2% in 2021, then fell by -6bps to 57.23% in 2022, then increased by 7bps to 61.04% in 2023, then grew by 2bps to 62.48% in 2024, then increased by 3bps to 64.14% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 64.14%, 64.52%, and 65.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.